Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population
SKU ID : MP-10559933 | Publishing Date : 01-Feb-2017 | No. of pages : 200
Detailed TOC of Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population
1. Executive Summary
Antiandrogens- Expanding Role of new Oral Antiandrogens in early treatment armamentarium of Prostate Cancer and Other indications-
Current Role of Oral antiandrogen therapy and its limitationso nmCRPC and HSPC- Next growth driver of New Oral Antiandrogens – ARN-509 or Xtandi or ODM-201- Who will win the race?o WW Targeted Patient population and expected Market size expansion of Anti androgens in each stageo Zytiga patent expiry – Game Changer in Antiandrogen Classo New Pipeline early stage Antiandrogens Targeting Xtandi and Zytiga Resistance population- A way to Fast track drug development?Immuno-Oncology drug –Potential in Prostate Cancer and ongoing combination studies with Antiandrogens & with Pipeline Prostate Cancer drugs
Other Late stage Pipeline drugs for treatment of Prostate Cancer- AKT inhibitors or PARP inhibitors or a new MoA combination with Antiandrogen- Competing to Xtandi/Zytiga or targeting Xtandi/Zytiga Resistance Population?2. Prostate Cancer
Stages of prostate cancer Signs and symptoms of prostate cancer Causes of prostate cancer Treatment of prostate cancer Unmet need of prostate cancer Current market size of prostate cancer3. Xtandi
Xtandi – current uptakeo Xtandi current US prescription trend and its uptake Xtandi Price issueo Xtandi uptake in Europeo Xtandi uptake in Japan Xtandi- additional opportunities in Prostate Cancero Xtandi in nmCRPC- PROSPER study Urology opportunity / Xtandi as a preferred urology drug Xtandi Market Potential in nmCRPC• Xtandi Price Issue in nmCRPC• Xtandi duration of therapy in nmCRPCo Xtandi – additional clinical trials in Prostate Cancer Xtandi in M1 Hormone Sensitive patients Xtandi in Mo Hormone Sensitive patients Xtandi other ongoing clinical studieso Xtandi with Pfizer early stage Prostate cancer Pipeline drug Xtandi in Other Indicationso Xtandi Potential in Breast Cancero Xtandi in Hepatocellular Carcinoma Xtandi in combination with New pipeline drugs Xtandi with IO combo- please refer chapter no. 74. Zytiga +ARN-509- How big is it has potential to change the treatment paradigm of Prostate Cancer? A competitive threat post Zytiga patent expiry for Xtandi?
Zytiga generic entry: An opportunity for ARN-509 or A threat for JNJ? Zytiga patent Expiry- more worries for early entry in US market than Ex-US Use patents of Zytiga : the 438 Patent Ongoing clinical trial of Zytiga with ARN-509 Ongoing clinical trials of Zytiga with Xtandi New formulation under development for Zytiga/Xtandi Combination studies of Zytiga with other targeted therapy vs. combination study of Xtandi with other targeted therapies, Ongoing Clinical trials Combination of Zytiga with Onapristone5. Pipeline Antiandrogens: Androgen Receptor Inhibitors vs. Androgen Synthesis inhibitors-
Androgen Receptor inhibitors: Who could be the major threat to Xtandi?• ARN-509- A better Xtandi is in makingo Ongoing Clinical trials of ARN-509 and our expectationso ARN-509- Clinical data comparison vs. Xtandi and other pipeline candidates• ODM-201- Does its safety differentiate it against ARN-509/Xtandi?• ODM-201 and ODM-204 has potential to challenge current leader Xtandi and Zytiga• EPI-001 and EPI-506• SHR3680• GT0918 (Proxalutamide)• ONC1-13B Other early stage pipeline Antiandrogens and our view – • DR103• AZD3514• HE3232 (Apoptone)• BMS-641988 AndrogenList of Figures, Tables and Charts Available in Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population
List Of Tables
Table 1: Competitive landscape of phase I/II clinical data comparison of ARN-509 vs.
Enzalutamide vs. ODM-201Table 2: Non metastatic CRPC- phase I/II clinical data comparison of ARN-508 vs. Enzalutamide vs. ODM-201- long term safety profile in Ph III is key to watchTable 3: Competitive landscape of mHSPC- STAMPEDE study data raise bar for newer AntiandrogenTable 4: Key study status of IO combination studies for prostate cancerTable 5: Stages of prostate cancer and its therapeutic options with drugsTable 6: Calculation of Targeted patient population Prechemo/Postchemo-US geographyTable 7: Reported sales of Xtandi/ Zytiga Table 8: Sales of drugs in 2014 and 2015Table 9: Reported sales of XtandiTable 10: Completed study of Xtandi in prostate cancerTable 11: Subgroup analysis shows benefit in MOTable 12: Ongoing study of Xtandi in prostate cancerTable 13: Xtandi market potential Table 14: Price related Petition in USTable 15: Treatment to rPFS would extend duration in TERRAIN studyTable 16: Xtandi ongoing clinical trials in breast cancerTable 17: Xtandi ongoing clinical trials in other indicationTable 18: Reported sales of ZytigaTable 19: List of companies who filed PARA IVTable 20: Ongoing clinical trials of ZytigaTable 21: Prostate cancer Xtandi vs. Zytiga in post chemo patientsTable 22: Pipeline androgen receptor inhibitorTable 23: Upregulated GR protein expressionTable 24: Ongoing clinical trials of ARN-509Table 25: AR affinity of newer antiandrogenTable 26: Ongoing clinical trials of ODM-201Table 27: ODM-201 clinical studiesTable 28: ODM-201 patient type in dualides studyTable 29: Ongoing clinical trials of ODM-204 Table 30: Targeted product profile in mCRPCTable 31: Ongoing clinical trials of EPI-506Table 32: AZD3514 Ph I clinical data in prostate cancerTable 33: Clinical trial status of TOK-001Table 34: Ongoing clinical trials of VT-464Table 35: List of androgen receptor inhibitor discontinued or on hold due to various reasonsTable 36: AR-V7+ had poor responses regardless of therapyTable 37: Possible MOA of resistance with Xtandi and ZytigaTable 38: Pipeline drugs for Prostate cancer treatment in combination with IO therapyTable 39: New pipeline drugs for Prostate cancerTable 40: Clinical trial study design of ADXS 31-1-42+ Pembrolizumab
List of Figures
Chart 1: Zytiga and Xtandi weekly TRx since Oct 2013
Chart 2: Zytiga and Xtandi weekly NBRx since Oct 2013Chart 3: Prostate Cancer Current and Future Treatment OptionsChart 4: Natural history of Prostate cancer Chart 5: Difference in Scrips given by Urology and OncologyChart 6: Comparison of recent TRx share trendsChart 7: Ongoing Xtandi trials targeting earlier stage prostate cancer patients and Market size Chart 8: Quarterly net sales of novel hormonal therapiesChart 9: Xtandi- Duration of Therapy in Various StudyChart 10: Distribution of various breast cancer subtypesChart 11: Xtandi Addressable Patient Population in US to treat Breast CancerChart 12: ODM-201- Permeability to Blood Brain BarrierChart 13: Efficacy Results from Phase 1 study of ODM-201Chart 14: ODM-201-how it is different from Xtandi and ARN-509Chart 15: ODM-204- A derived structure from Zytiga and XtandiChart 16: Positioning of ODM-204Chart 17: Target product profile in mCRPCChart 18: EPI-506- Androgen Receptor Binding SiteChart 19: Trial designee of EPI 506Chart 20: EPI-506- Target Prostate Cancer PatientChart 21: APOPTONE in preclinical model in CRPCChart 22: Phase 3 study size for TOK-001 vs. Xtandi/ZytigaChart 23: OncoGenex – Mechanism of ActionChart 24: ARV-330 – Mechanism of ActionChart 25: PROTAC Platform of Arvinas PharmaceuticalsChart 26: Emerging mechanisms of Resistance to Xtandi/ZytigaChart 27: Xtandi/Zytiga- Shorter rPFS of AR-V7+ PatientsChart 28: MOA of Action of ADX- PSA Chart 29: Recognized Prostate Cancer Cells by ADX-PSAChart 30: Killed cancer cells by ADX- PSAChart 31: Step by Step Lm-LLo Immuno modulation of PembrolizumabChart 32: REIC/ Dkk-3 – Western Blot AnalysisChart 33: Dendritic CellsChart 34: Clinical Trial study design of NBTXR3 in Prostate CancerChart 35: Preliminary Efficacy of Osteodex in CancerChart 36: MOA of MipsagarginChart 37: MVI-816 (pTVG-HP) Plasmid DNA Vaccine Targeting PAPChart 38: MOA of AKT inhibitor –Ipatasertib Chart 39: MOA of AKT inhibitor –LY3023414 (PH II)